State of Alaska Department of Revenue reduced its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 4.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,815 shares of the specialty pharmaceutical company’s stock after selling 353 shares during the period. State of Alaska Department of Revenue’s holdings in Jazz Pharmaceuticals were worth $974,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in Jazz Pharmaceuticals in the first quarter valued at approximately $25,000. Enlightenment Research LLC purchased a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $37,000. First Hawaiian Bank raised its holdings in Jazz Pharmaceuticals by 42.2% in the fourth quarter. First Hawaiian Bank now owns 320 shares of the specialty pharmaceutical company’s stock valued at $39,000 after buying an additional 95 shares during the period. Legacy Financial Advisors Inc. purchased a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $56,000. Finally, Eukles Asset Management purchased a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $102,000. Institutional investors and hedge funds own 93.41% of the company’s stock.

In other news, CFO Matthew P. Young sold 1,916 shares of the firm’s stock in a transaction that occurred on Wednesday, February 27th. The shares were sold at an average price of $131.46, for a total transaction of $251,877.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Suzanne Sawochka Hooper sold 6,666 shares of the firm’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $140.00, for a total transaction of $933,240.00. Following the sale, the executive vice president now directly owns 40,401 shares of the company’s stock, valued at approximately $5,656,140. The disclosure for this sale can be found here. Insiders have sold 11,668 shares of company stock valued at $1,606,567 in the last three months. Corporate insiders own 3.90% of the company’s stock.

Shares of NASDAQ:JAZZ opened at $128.44 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.57 and a quick ratio of 3.42. Jazz Pharmaceuticals PLC has a 52-week low of $113.52 and a 52-week high of $184.00. The company has a market capitalization of $7.33 billion, a price-to-earnings ratio of 10.49, a PEG ratio of 0.85 and a beta of 1.23.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, February 26th. The specialty pharmaceutical company reported $3.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.66 by $0.61. Jazz Pharmaceuticals had a net margin of 23.64% and a return on equity of 26.20%. The company had revenue of $476.46 million during the quarter, compared to the consensus estimate of $459.48 million. During the same quarter last year, the company earned $2.95 earnings per share. Jazz Pharmaceuticals’s revenue for the quarter was up 9.2% on a year-over-year basis. On average, analysts anticipate that Jazz Pharmaceuticals PLC will post 13.19 EPS for the current fiscal year.

JAZZ has been the topic of several research reports. Morgan Stanley cut their price target on shares of Jazz Pharmaceuticals from $168.00 to $135.00 and set an “equal weight” rating on the stock in a report on Friday, March 8th. BidaskClub lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 16th. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, February 14th. Cantor Fitzgerald set a $201.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Friday, January 4th. Finally, Royal Bank of Canada set a $184.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 18th. Two analysts have rated the stock with a sell rating, three have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $182.71.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/jazz-pharmaceuticals-plc-jazz-stake-decreased-by-state-of-alaska-department-of-revenue/2979290.html.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Story: What does the Producer Price Index (PPI) tell investors?

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.